AKARI Therapeutics Company
Akari is developing inhibitors of acute and chronic inflammation, specifically the complement and leukotriene systems, to treat rare and orphan diseases with unmet need.
Funding Status:
IPO
Industry:
Stem Cell Exhaustion
Employee Number:
11-50
Investment Stage:
N/A
Headquarters:
United States
Founded Date:
2005
Technology:
Scientifically-Validated Lifestyle Recommendation
Number Of Exists:
N/A
Investor Type:
N/A